Business Context and Reporting Period
This Form 8-K Current Report was filed by BRISTOL-MYERS SQUIBB CO on August 17, 2009. The filing addresses Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The report was submitted in response to a comment from the SEC staff regarding the disclosure of material agreements related to two major strategic alliances.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely to disclose the existence and terms of specific contractual agreements.
Material Changes and Disclosures
The primary material event is the submission of previously undisclosed or requested material agreements concerning:
- Sanofi-Aventis Alliance: Agreements regarding the codevelopment and cocommercialization of PLAVIX (clopidogrel bisulfate) and ISCOVER.
- Otsuka Pharmaceutical Alliance: Agreements regarding the codevelopment and cocommercialization of ABILIFY (aripiprazole).
The filing includes a comprehensive list of exhibits (10.1 through 10.14) detailing partnership bylaws, alliance support agreements, intellectual property licenses, and amendments dating from 1997 through April 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not explicitly list new risks or contingencies beyond the standard disclosure of the alliance terms. A note indicates that confidential treatment has been requested for certain portions of the exhibits, meaning specific financial terms or proprietary details within those agreements are omitted from this public filing.
Investor Verification Checklist
- Verify the specific financial terms (royalties, milestones, profit splits) in the confidential portions of the Sanofi and Otsuka agreements filed separately with the Commission.
- Review the impact of the April 4, 2009 amendment (Exhibit 10.14) to the Otsuka agreement on future revenue recognition for ABILIFY.
- Confirm the status of the PLAVIX patent and supply chain obligations under the 1997 and 2001 agreements with Sanofi.
- Check subsequent filings for any updates on the commercial performance of these co-promoted products.